In the clinical treatment of thyroid cancer (TC), immune checkpoint inhibitor therapy (ICT, mainly PD-1/PD-L1 monoclonal antibody therapy) is considered to be an important factor in tumor treatment due to its significant anti-tumor effect and limited side effects. This evidence concerns the gene CD274 and neoplasm.